Key result
Recombinant apo A-IM ETC-216 reduces atheroma volume by ~1% versus placebo over five weeks.
Why the study?
The identification of the apo A-IMilano variant, associated with low HDL but low prevalence of atherosclerosis, motivated exploration of recombinant apo A-IM as a therapeutic agent for atherosclerosis.
Does recombinant apo A-IM phospholipid complex reduce atherosclerotic burden in patients with atherosclerosis?
Population
72-year-old male patient case and families with apo A-IM variant
Comparison
Recombinant apo A-IM phospholipid complex (ETC-216) vs placebo
Design
Review including randomized controlled trial of recombinant apo A-IM
Follow-up
3 weeks after final dose
Authors
Loading...
Should not yet change practice; leaves open whether short-term atheroma reduction with ETC-216 improves outcomes.
Does recombinant apo A-IM phospholipid complex reduce atherosclerotic burden in patients with atherosclerosis?
Absolute Event Rate: 1.06% vs 0.14%
Recombinant apo A-I Milano (ETC-216) shows potential in regressing atherosclerotic plaques by mobilizing cholesterol from peripheral tissues, mimicking the atheroprotective effects seen in natural carriers of the variant.
Futterman et al. (2005) conducted a review in Atherosclerosis. Recombinant apo A-IM phospholipid complex (ETC-216) vs. Placebo was evaluated on Decrease in atheroma volume assessed by intravascular ultrasound (IVUS). Recombinant apo A-IM phospholipid complex (ETC-216) administered intravenously for 5 weeks decreased atheroma volume by 1.06% compared to 0.14% with placebo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: